Cardiome Reports Third Quarter Results

NASDAQ: CRME TSX: COM

VANCOUVER, Nov. 9 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME
/ TSX: COM) today reported financial results for the third quarter ended
September 30, 2009. Amounts, unless specified otherwise, are expressed in
Canadian dollars and in accordance with Canadian Generally Accepted Accounting
Principles (Canadian GAAP). At close of business on September 30, 2009, the
exchange rate was CAD$1.00=US$0.9340.

Results of Operations

We recorded a net loss of $0.4 million ($0.01 per common share) for the three
months ended September 30, 2009 ("Q3-2009"), compared to a net loss of $11.8
million ($0.18 per common share) for the three months ended September 30, 2008
("Q3-2008"). The decrease in net loss for the current quarter was largely due
to the recognition of deferred revenue related to the upfront payment of
U.S.$60 million and milestone payment of U.S.$15 million from our
collaborative partner Merck & Co., partially offset by a foreign exchange loss
on translation of U.S. denominated net monetary assets into Canadian dollars
for reporting purposes at period end.
Revenue for Q3-2009 was $21.1 million, an increase of $20.6 million from $0.5
million in Q3-2008.
Research and development expenditures were $10.3 million for Q3-2009, compared
to $8.5 million for Q3-2008. The increase is due to increased expenditures for
vernakalant (iv) related to the ongoing Phase 3 European comparator study and
for GED-aPC related to completing work on the Phase 1 clinical trial. This
increase was partially offset by decreased expenditures for vernakalant (oral)
as development efforts for this program globally are now the responsibility of
Merck. General and administration expenditures for Q3-2009 were $4.7 million,
compared to $4.8 million for Q2-2008. Amortization for Q3-2009 was $0.8
million compared to $0.9 million for Q3-2008. Interest and other income was
$0.1 million for Q3-2009 and $0.2 million for Q3-2008. Foreign exchange loss
was $5.7 million in Q3-2009 compared to a foreign exchange gain of $1.7
million in Q3-2008.
Stock-based compensation, a non-cash item included in operating expenses,
increased to $1.8 million for Q3-2009, as compared to $0.5 million for
Q3-2008.

Liquidity and Outstanding Share Capital

At September 30, 2009, we had cash and cash equivalents of $84.4 million. As
of November 6, 2009, the Company had 60,163,911 common shares issued and
outstanding, and 6,688,788 common shares issuable upon the exercise of
outstanding stock options at a weighted-average exercise price of $7.30 per
share. In October 2009, 2,272,727 Series A Preferred shares were converted to
common shares on a 1-to-1 basis. No Series A Preferred shares remain
outstanding. In October 2009, we announced that on expiry of a modified "Dutch
auction" tender offer announced in August 2009, we purchased for cancellation
6,470,588 of our common shares at US$4.25 per share for an aggregate purchase
price of U.S.$27.5 million.

Conference Call Notification

Cardiome will hold its quarterly teleconference and webcast at 9:00am Eastern
(6:00am Pacific) on Monday, November 9, 2009. To access the conference call,
please dial 416-695-7806 or 888-789-9572 and reference conference 2345242.
There will be a separate dial-in line for analysts on which we will respond to
questions at the end of the call. The webcast can be accessed through
Cardiome's website at www.cardiome.com.
Webcast and telephone replays of the conference call will be available
approximately two hours after the completion of the call through December 9,
2009. Please dial 416-695-5800 or 800-408-3053 and enter code 3147267 followed
by the number sign to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated
to the advancement and commercialization of novel treatments for disorders of
the heart and circulatory system. Cardiome is traded on the NASDAQ National
Market (CRME) and the Toronto Stock Exchange (COM). For more information,
please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for
negotiating additional corporate collaborations or licensing arrangements and
their timing. Specifically, certain risks and uncertainties that could cause
such actual events or results expressed or implied by such forward-looking
statements and information to differ materially from any future events or
results expressed or implied by such statements and information include, but
are not limited to, the risks and uncertainties that: we, together with our
collaborative partners, may not be able to successfully develop and obtain
regulatory approval for vernakalant (iv) or vernakalant (oral) in the
treatment of atrial fibrillation or any other current or future products in
our targeted indications; our future operating results are uncertain and
likely to fluctuate; we may not be able to raise additional capital; we may
not be successful in establishing additional corporate collaborations or
licensing arrangements; we may not be able to establish marketing and sales
capabilities and the costs of launching our products may be greater than
anticipated; we rely on third parties for the continued supply and manufacture
of vernakalant (iv) and vernakalant (oral) and we have no experience in
commercial manufacturing; we may face unknown risks related to intellectual
property matters; we face increased competition from pharmaceutical and
biotechnology companies; and other factors as described in detail in our
filings with the Securities and Exchange Commission available at www.sec.gov
and the Canadian securities regulatory authorities at www.sedar.com. Given
these risks and uncertainties, you are cautioned not to place undue reliance
on such forward-looking statements and information, which are qualified in
their entirety by this cautionary statement. All forward-looking statements
and information made herein are based on our current expectations and we
undertake no obligation to revise or update such forward-looking statements
and information to reflect subsequent events or circumstances, except as
required by law.

SOURCE Cardiome Pharma Corp.

Peter K. Hofman, Senior Director, Investor Relations, (604) 676-6993 or Toll
Free: 1-800-330-9928, Email: phofman@cardiome.com